The results suggest that tranplantation of such in vitro enriched and expanded OCT4-specific CD8+ CIK cells may improve the specific immune defense mechanism against CSC, providing a novel avenue of CSC targeted immunotherapy for clinical treatment of ovarian cancer. This evidence concerns the gene CD8A and ovarian cancer.